+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects



Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects



American Journal of Cardiology 93(1): 31-39



The effects of atorvastatin at 20, 40, and 80 mg/day on plasma lipoprotein subspecies were examined in a randomized, placebo-controlled fashion over 36 weeks in 97 patients with coronary heart disease (CHD) with low-density lipoprotein (LDL) cholesterol levels of >130 mg/dl and compared directly with the effects of fluvastatin (n = 28), pravastatin (n = 22), lovastatin (n = 24), and simvastatin (n = 25). The effects of placebo and 40 mg/day of each statin were also examined in subjects with CHD with subjects in the fasting state and in the fed state 4 hours after a meal rich in saturated fat and cholesterol and compared with results in age- and gender-matched control subjects. At all doses tested in the fasting and fed states, atorvastatin was significantly (p <0.01) more effective in lowering LDL cholesterol and non-high-density lipoprotein (HDL) cholesterol than all other statins, and significantly (p <0.05) more effective than all statins, except for simvastatin, in lowering triglyceride and remnant lipoprotein (RLP) cholesterol. At 40 mg/day in the fasting state, atorvastatin was significantly (p <0.01) more effective than all statins, except for lovastatin and simvastatin, in lowering cholesterol levels in small LDL, and was significantly (p <0.05) more effective than all statins, except for simvastatin, in increasing cholesterol in large HDL and in lowering LDL particle numbers. Our data indicate that atorvastatin was the most effective statin tested in lowering cholesterol in LDL, non-HDL, and RLP in the fasting and fed states, and getting patients with CHD to established goals, with fluvastatin, pravastatin, lovastatin, and simvastatin having about 33%, 50%, 60%, and 85% of the efficacy of atorvastatin, respectively, at the same dose in the same patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 048608536

Download citation: RISBibTeXText

PMID: 14697462


Related references

Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. American Journal of Cardiology 95(9): 1025-1032, 2005

Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. American Journal of Cardiology 90(7): 689-696, October 1, 2002

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and Fluvastatin in patients with hypercholesterolemia (The CURVES Study). American Journal of Cardiology 81(5): 582-587, 1998

Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. Journal of Family Practice 47(5): 349-356, 1998

Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clinical Pharmacokinetics 47(7): 463-474, 2008

Comparison of the dose efficacy of atorvastatin with pravastatin, simvastatin, fluvastatin and lovastatin The CURVES study. European Heart Journal 18(ABSTR SUPPL ): 371, 1997

Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. American Journal of Cardiology 88(10): 1129-1133, November 15, 2001

Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. Clinical Cardiology 33(4): 222-227, 2010

Increased postprandial remnant like particles Cholesterol in hemodialysed patients with coronary heart disease. Atorvastatin decreases fasting and postprandial RLP-cholesterol and RLP-triglycerides. Atherosclerosis 144(Supp-S1): 124-125, 1999

The efficacy and safety of atorvastatin compared with simvastatin, lovastatin and pravastatin in patients with hypercholesterolaemia. European Heart Journal 18(ABSTR SUPPL ): 372, 1997

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. Journal of Clinical Pathology 57(7): 728-734, 2004

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. American Journal of Kidney Diseases 43(4): 589-599, 2004

Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits. Arquivos Brasileiros de Cardiologia 84(4): 314-319, 2005

Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes, Obesity and Metabolism 2(6): 355-362, 2001

Efficacy and safety of atorvastatin versus simvastatin in type II diabetes patients with coronary heart disease. European Heart Journal 20(ABSTR SUPPL ): 177, 1999